Finerenone approved in Japan for treatment of patients with chronic heart failure – Bayer
Bayer announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved finerenone (Kerendia), a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), for the treatment of adult patients… read more.
